To carry out a comparative therapeutic and economic evaluation of a) clozapine in treatment-resistantschizophrenic patients or those suffering from debilitating adverse effects from conventional phenothiazines; and of b) risperidone as first line therapy for patients with schizophrenia, and in patients suffering from adverse effects from phenothiazines.